l*******2
发帖数: 1 | 1 【 以下文字转载自 Military 讨论区 】
发信人: lubbock12 (非老非小将), 信区: Military
标 题: yahoo浓墨重彩隆重介绍季博士的STI-2020DNA 抗体
发信站: BBS 未名空间站 (Thu Sep 3 08:20:46 2020, 美东)
肌肉注射DNA 质粒抗体代替新冠疫苗，牛逼！
https://www.google.com/amp/s/finance.yahoo.com/amphtml/news/sorrento-
announces-closing-acquisition-smartpharm-130000645.html
Sorrento Announces the Closing of Its Acquisition of SmartPharm to Build
Next Generation G-MAB-Encoded Plasmid DNA For Cost-Efficient and In Vivo
Production of Antibody Therapeutics in Patients
Sorrento Therapeutics, Inc.
September 2, 2020, 9:00 am
SAN DIEGO and BOSTON, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Sorrento
Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and SmartPharm Therapeutics,
Inc. (“SmartPharm”) announced today that Sorrento has completed the
acquisition of SmartPharm, a gene-encoded protein therapeutics company
developing non-viral DNA and RNA gene delivery platforms for COVID-19 and
rare diseases with broad potential application in enhancing any antibody-
centric therapeutics.
The platform in synergy with Sorrento’s industry-leading fully human G-MAB&
#8482; antibody library has the potential to be the engine for the next-
generation, cost-effective in vivo production of antibody therapeutics in
patients. By encoding the antibody sequence into a plasmid, a single
injection into someone’s muscle could potentially lead the person to make
their own antibodies in vivo for months, instead of relying on repeat
administrations of an externally manufactured antibody.
“We are very encouraged by the preclinical data generated thus far by our
STI-2020dna plasmid candidate against COVID-19,” said Henry Ji, Ph.D., CEO
of Sorrento Therapeutics. “But beyond STI-2020dna the integration of the
plasmid DNA technology with our existing antibody products has the potential
to make antibody therapy much more accessible and affordable for patients,
and is applicable to a multitude of indications ranging from cancer to
infectious diseases.” |
|
